Skip to main content
Premium Trial:

Request an Annual Quote

Ingenium to Create Animal Models for Grnenthal

NEW YORK, Feb. 25 (GenomeWeb News) - Ingenium Pharmaceuticals will develop animal models with defined gene mutations for Gr nenthal, the German companies said today.


Ingenium, of Munich, will utilize its Ingenotyping technology, which enables it to create in four months a series of mammalian models carrying genetic alterations in any target gene of interest, according to the company.


Gr nenthal, based in Aachen, plans to use the animal models resulting from the collaboration to validate targets for the treatment of pain.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.